Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of GIP and GLP-1 in HNF1A-diabetes
NCT03081676Phase 1Completed
- Sponsor
- Gentofte Hospital
- Start
- Mar 2017
- Primary completion
- Jun 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of glucose-dependent insulinotropic polypeptide[1-42] and Glucagon-like peptide 1 in maturity-onset diabetes of the young type 3 (6 arms), sponsored by Gentofte Hospital. Primary endpoint: Insulin secretion. Started Mar 2017; status: completed.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]Glucagon-like peptide 1
03
Conditions
maturity-onset diabetes of the young type 3
Beyond the preview
Go deeper on NCT03081676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081676.